Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 Promising Penny Stocks With Market Caps Over US$4B

In This Article:

Global markets have experienced a turbulent start to the year, with U.S. equities declining amid inflation concerns and political uncertainty, while European indices showed resilience. In such fluctuating market conditions, investors often seek opportunities beyond the well-known large-cap stocks. Penny stocks, a term that may seem outdated but still relevant today, typically refer to smaller or newer companies that can offer surprising value and growth potential when backed by strong financials.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

Polar Capital Holdings (AIM:POLR)

£5.00

£481.98M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.50

MYR2.49B

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.68

£420.17M

★★★★★★

ME Group International (LSE:MEGP)

£2.045

£770.58M

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.875

MYR290.45M

★★★★★★

Lever Style (SEHK:1346)

HK$0.99

HK$628.44M

★★★★★★

Stelrad Group (LSE:SRAD)

£1.415

£180.2M

★★★★★☆

Secure Trust Bank (LSE:STB)

£3.58

£68.28M

★★★★☆☆

Starflex (SET:SFLEX)

THB2.56

THB1.97B

★★★★☆☆

Embark Early Education (ASX:EVO)

A$0.785

A$142.2M

★★★★☆☆

Click here to see the full list of 5,708 stocks from our Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Alibaba Health Information Technology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Alibaba Health Information Technology Limited operates in pharmaceutical direct sales, e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of approximately HK$52.91 billion.

Operations: The company generated CN¥28.34 billion from its Distribution & Development of Pharmaceutical & Healthcare Business segment.

Market Cap: HK$52.91B

Alibaba Health Information Technology Limited, with a market cap of approximately HK$52.91 billion, has shown significant financial activity in its pharmaceutical and healthcare business segment, generating CN¥28.34 billion. The company remains debt-free and has stable short-term assets exceeding liabilities by CN¥7 billion. Recent earnings reports indicate growth, with sales rising to CN¥14.27 billion for the half-year ending September 2024, up from CN¥12.96 billion the previous year, while net income increased to CN¥768.95 million from CN¥445.89 million year-on-year. Despite a low return on equity of 7.9%, earnings have grown significantly over the past five years at an average rate of 53.3% per year.